Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Emilio Iannitto, Monica Balzarotti, Maurizio Martelli, Pier Luigi Zinzani, Alessandra Tucci, Alice Di Rocco, Federica Cavallo, Sara Usai, Anna Guidetti, Emanuele Ravano, Franceso Merli, Barbara Botto, Matteo Pelosini, Cristina Tecchio, Michele Spina, Enrico Derenzini, Silvia Finotto, Brunella Mola, Antonio Pinto, Manuela Zanni, Roberta Battistini, Stefan Hohaus, Irene Dogliotti, Guido Gini, Vittorio Ruggero Zilioli, Sonya De Lorenzo, Anna Dodero, Alessandro Broccoli, Alessandro Maggi, Clara Mannarella, Annalisa Chiarenza, Domenico Pastore, Pellegrino Musto, Caterina Stelitano, Francesco Di Raimondo, Nicola Cascavilla, Nicola Di Renzo, Marilena Salerno, Renato Scalone, Luca Nassi, Attilio Guarini, Caterina Patti, Vita Polizzi, Gabriella Amato, Giovannino Ciccone, Andrea Evangelista, Agostino La Porta, Angelo Genua, Donato Mannina, Ciro Maria Improta, Alessandro Re, Fabrizio Lo Presti, Rosalba Donatella Calogero, Maurizio Musso, Ugo Consoli

Blood (2023) 142 (Supplement 1): 986.

https://doi.org/10.1182/blood-2023-178197

Published: 2023

Journal Articles

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Blood (2023) 142 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2023-178648

Published: 2023

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 1313–1315.

https://doi.org/10.1182/blood-2022-166225

Published: 2022

Journal Articles

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Blood (2022) 140 (Supplement 1): 3638–3641.

https://doi.org/10.1182/blood-2022-165977

Published: 2022

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 384.

https://doi.org/10.1182/blood-2021-153364

Published: 2021

Journal Articles

Antiemetic Prophylaxis with NEPA (NETUPITANT/PALONOSETRON) and Dexamethasone to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) in Hodgkin'S Lymphoma Naïve Patients Receiving ABVD Regimen: A Multicenter Phase Iia Study

Daniela Nasso, Silvia Bolis, MD, Elisabetta Abruzzese, MD, Ilaria Romano, Caterina Patti, MD, Nicola Di Renzo, MD, Leonardo Flenghi, Caterina Stelitano, MD, Donato Mannina, MD, Marianna Sassone, MD, Alberto De Stefano, Carlo Chiaramonte, Cristiano Tesei, Ida Provenzano, Maria Cantonetti, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-139297

Published: 2020

Journal Articles

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136633

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Sarit Assouline, MD, Shen Li, MD, Christian Gisselbrecht, MD, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, MD, Lois E. Shepherd, Norbert Schmitz, MD, Tara Baetz, Armand Keating, MD, Sue Robinson, MD, Matthew D. Seftel, FRCP,FRCPC,MPH,MD, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump, MD FRCPC

Blood (2019) 134 (Supplement_1): 768.

https://doi.org/10.1182/blood-2019-124879

Published: 2019

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi

Blood (2018) 132 (Supplement 1): 393.

https://doi.org/10.1182/blood-2018-99-115827

Published: 2018

Journal Articles

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

Blood (2018) 132 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2018-99-116060

Published: 2018

Journal Articles

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Blood (2017) 130 (Supplement 1): 4010.

https://doi.org/10.1182/blood.V130.Suppl_1.4010.4010

Published: 2017

Journal Articles

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Blood (2017) 130 (Supplement 1): 4062.

https://doi.org/10.1182/blood.V130.Suppl_1.4062.4062

Published: 2017

NARROW

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Antiemetic Prophylaxis with NEPA (NETUPITANT/PALONOSETRON) and Dexamethasone to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) in Hodgkin'S Lymphoma Naïve Patients Receiving ABVD Regimen: A Multicenter Phase Iia Study

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi

Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only